Abstract
With a total of 192,280 new cases predicted for 2009, prostate cancer (PC) now accounts for 25% of all new male cancers diagnosed in the United States [1]. Furthermore, in their lifetime, one in six men will be clinically diagnosed with having PC, although many more men are found to have histological evidence of PC at autopsy [2,3,4]. Presently, approximately 1 in 10 men will die of PC [5,6]. The ever-aging population and wider spread use of the blood prostate-specific antigen (PSA) test [7,8], as well as the tendency to apply lower cut-off levels for this test [9], will further increase the diagnosis of this disease [10].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J.: Cancer Statistics, 2009. CA Cancer J. Clin. 59(4), 225–249 (2009)
Carter, H.B., Piantadosi, S., Isaacs, J.T.: Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 143(4), 742–746 (1990)
Parkin, D.M., Bray, F.I., Devesa, S.S.: Cancer burden in the year 2000. the global picture. Eur J Cancer 37(suppl. 8), S4–S66 (2001)
Konety, B., Bird, V., Deorah, S., Dahmoush, L.: Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. The Journal of Urology 174(5), 1785–1788 (2005)
Crawford, E.D.: Epidemiology of prostate cancer. Urology 62(6 suppl. 1), 3–12 (2003)
Stewart, S.L., King, J.B., Thompson, T.D., Friedman, C., Wingo, P.A.: Cancer mortality surveillance–united states, 1990-2000. MMWR Surveill Summ 53(3), 1–108 (2004)
Catalona, W.J., Loeb, S., Han, M.: Viewpoint: expanding prostate cancer screening. Ann. Intern. Med. 144(6), 441–443 (2006)
Hoffman, R.M.: Viewpoint: limiting prostate cancer screening. Ann. Intern. Med. 144(6), 438–440 (2006)
Graif, T., Loeb, S., Roehl, K.A., Gashti, S.N., Griffin, C., Yu, X., Catalona, W.J.: Under diagnosis and over diagnosis of prostate cancer. J. Urol. 178(1), 88–92 (2007)
Max, W., Rice, D.P., Sung, H.Y., Michel, M., Breuer, W., Zhang, X.: The economic burden of prostate cancer, california, 1998. Cancer 94(11), 2906–2913 (2002)
Mangar, S.A., Huddart, R.A., Parker, C.C., Dearnaley, D.P., Khoo, V.S., Horwich, A.: Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur. J. cancer 41(6), 908–921 (2005)
Meraney, A.M., Haese, A., Palisaar, J., Graefen, M., Steuber, T., Huland, H., Klein, E.A.: Surgical management of prostate cancer: advances based on a rational approach to the data. Eur. J. Cancer 41(6), 888–907 (2005)
Bucci, M.K., Bevan, A., Roach III, M.: Advances in radiation therapy: conventional to 3d, to imrt, to 4d, and beyond. CA Cancer J. Clin. 55(2), 117–134 (2005)
Hricak, H., Wang, L., Wei, D.C., Coakley, F.V., Akin, O., Reuter, V.E., Gonen, M., Kattan, M.W., Onyebuchi, C.N., Scardino, P.T.: The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 100(12), 2655–2663 (2004)
Cellini, N., Morganti, A.G., Mattiucci, G.C., Valentini, V., Leone, M., Luzi, S., Manfredi, R., Dinapoli, N., Digesu, C., Smaniotto, D.: Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int. J. Radiat. Oncol. Biol. Phys. 53(3), 595–599 (2002)
Roach, M.: Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urologic Clinics of North America 31(2), 353–366 (2004)
Baxter, N.N., Tepper, J.E., Durham, S.B., Rothenberger, D.A., Virnig, B.A.: Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 128(4), 819–824 (2005)
Steyn, J.H., Smith, F.W.: Nuclear magnetic resonance imaging of the prostate. Br. J. Urol. 54(6), 726–728 (1982)
Hricak, H., Williams, R.D., Spring, D.B., Moon Jr., K.L., Hedgcock, M.W., Watson, R.A., Crooks, L.E.: Anatomy and pathology of the male pelvis by magnetic resonance imaging. AJR Am. J. Roentgenol. 141(6), 1101–1110 (1983)
Villeirs, G.M., Oosterlinck, W., Vanherreweghe, E., De Meerleer, G.O.: A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur. J. Radiol. 73(2), 352–356 (2010)
Tanimoto, A., Nakashima, J., Kohno, H., Shinmoto, H., Kuribayashi, S.: Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic mr imaging in combination with t2-weighted imaging. J. Magn. Reson. Imaging 25(1), 146–152 (2007)
Scheenen, T.W., Klomp, D.W., Roll, S.A., Futterer, J.J., Barentsz, J.O., Heerschap, A.: Fast acquisition-weighted three-dimensional proton mr spectroscopic imaging of the human prostate. Magn. Reson. Med. 52(1), 80–88 (2004)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fütterer, J.J. (2010). Prostate Cancer MR Imaging. In: Madabhushi, A., Dowling, J., Yan, P., Fenster, A., Abolmaesumi, P., Hata, N. (eds) Prostate Cancer Imaging. Computer-Aided Diagnosis, Prognosis, and Intervention. Prostate Cancer Imaging 2010. Lecture Notes in Computer Science, vol 6367. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-15989-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-15989-3_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-15988-6
Online ISBN: 978-3-642-15989-3
eBook Packages: Computer ScienceComputer Science (R0)